Aptose Biosciences Inc. - Common Shares Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q1 2025

Type / Class
Equity / Common Shares
Shares outstanding
2,556,332
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aptose Biosciences Inc. - Common Shares based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Hanmi Pharmaceutical Co., Ltd. 20% $115,375 508,710 Hanmi Pharmaceutical Co., Ltd. 18 Mar 2025

Institutional Holders of Aptose Biosciences Inc. - Common Shares across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$4,414 0
2024 Q4 19,592 $4,414 +$4,393 $0.23 2
2024 Q3 92 $38 $0.41 1
2024 Q2 92 $70 -$44,000 $0.76 1
2024 Q1 26,758 $44,153 -$79,202 $1.66 2
2023 Q4 74,758 $188,234 $2.53 2
2023 Q3 74,758 $209,258 +$59,717 $2.80 2
2023 Q2 53,424 $247,427 -$16,354,051 $4.64 2
2023 Q1 20,962,406 $13,416,873 -$1,028,939 $0.64 44
2022 Q4 22,970,643 $13,320,850 -$985,663 $0.58 48
2022 Q3 24,557,699 $14,615,453 -$318,301 $0.60 47
2022 Q2 25,058,806 $18,646,507 -$2,734,410 $0.74 43
2022 Q1 28,531,682 $38,807,613 -$3,580,687 $1.36 51
2021 Q4 31,179,158 $42,369,792 -$20,800,165 $1.35 57
2021 Q3 39,570,451 $86,350,850 -$22,510,362 $2.18 63
2021 Q2 47,225,004 $156,739,083 -$38,364,376 $3.32 62
2021 Q1 52,369,697 $312,930,503 +$27,233,992 $5.98 71
2020 Q4 48,718,160 $213,602,858 -$10,658,227 $4.38 65
2020 Q3 46,407,177 $278,292,363 +$62,519,881 $6.00 64
2020 Q2 35,924,634 $226,542,479 +$5,200,153 $6.31 57
2020 Q1 34,928,326 $207,138,467 +$26,188,083 $5.94 52
2019 Q4 30,725,365 $174,227,455 +$81,216,464 $5.67 56
2019 Q3 14,207,658 $29,579,615 +$4,633,211 $2.08 31
2019 Q2 11,921,350 $31,121,540 +$22,562,599 $2.61 29
2019 Q1 3,295,238 $6,621,532 +$429,262 $2.00 21
2018 Q4 3,093,398 $5,909,239 +$3,413,791 $1.91 20
2018 Q3 1,240,646 $3,226,577 +$974,193 $2.60 16
2018 Q2 846,761 $3,289,881 +$1,457,654 $3.94 22
2018 Q1 479,837 $1,515,652 +$466,220 $3.17 16
2017 Q4 365,569 $817,067 +$418,875 $2.24 15
2017 Q3 177,400 $263,585 -$1,105,838 $1.48 11
2017 Q2 1,088,212 $1,338,627 -$1,369,601 $1.23 7
2017 Q1 2,435,040 $2,477,698 -$373,142 $1.03 10
2016 Q4 2,688,809 $3,664,000 -$283,788 $1.40 11
2016 Q3 2,899,922 $6,532,018 +$885,330 $2.25 10
2016 Q2 2,504,257 $6,161,020 -$322,238 $2.44 10
2016 Q1 2,628,108 $7,734,020 -$22,658 $2.95 12
2015 Q4 2,633,101 $6,766,012 -$502,487 $2.54 10
2015 Q3 2,751,269 $11,960,000 -$2,117,621 $4.31 12
2015 Q2 3,132,610 $16,322,000 +$1,360,898 $5.10 15
2015 Q1 2,921,962 $15,775,000 -$1,285,757 $5.42 13
2014 Q4 3,158,681 $18,681,000 +$18,658,000 $5.92 7